![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: NLRP12 |
Gene summary for NLRP12 |
![]() |
Gene information | Species | Human | Gene symbol | NLRP12 | Gene ID | 91662 |
Gene name | NLR family pyrin domain containing 12 | |
Gene Alias | CLR19.3 | |
Cytomap | 19q13.42 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P59046 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
91662 | NLRP12 | HCC1 | Human | Liver | HCC | 1.26e-03 | 7.84e-01 | 0.5336 |
91662 | NLRP12 | HCC2 | Human | Liver | HCC | 3.31e-08 | 1.06e+00 | 0.5341 |
91662 | NLRP12 | HCC5 | Human | Liver | HCC | 2.01e-12 | 7.90e-01 | 0.4932 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004586222 | Liver | HCC | positive regulation of proteolysis | 232/7958 | 372/18723 | 5.66e-15 | 3.98e-13 | 232 |
GO:001056322 | Liver | HCC | negative regulation of phosphorus metabolic process | 259/7958 | 442/18723 | 4.29e-12 | 1.92e-10 | 259 |
GO:004593622 | Liver | HCC | negative regulation of phosphate metabolic process | 258/7958 | 441/18723 | 6.00e-12 | 2.60e-10 | 258 |
GO:004232622 | Liver | HCC | negative regulation of phosphorylation | 227/7958 | 385/18723 | 3.98e-11 | 1.52e-09 | 227 |
GO:000193322 | Liver | HCC | negative regulation of protein phosphorylation | 196/7958 | 342/18723 | 1.95e-08 | 4.63e-07 | 196 |
GO:004328112 | Liver | HCC | regulation of cysteine-type endopeptidase activity involved in apoptotic process | 125/7958 | 209/18723 | 3.12e-07 | 5.42e-06 | 125 |
GO:200011612 | Liver | HCC | regulation of cysteine-type endopeptidase activity | 137/7958 | 235/18723 | 6.91e-07 | 1.08e-05 | 137 |
GO:005254722 | Liver | HCC | regulation of peptidase activity | 247/7958 | 461/18723 | 8.28e-07 | 1.27e-05 | 247 |
GO:005254822 | Liver | HCC | regulation of endopeptidase activity | 230/7958 | 432/18723 | 3.58e-06 | 4.68e-05 | 230 |
GO:000724912 | Liver | HCC | I-kappaB kinase/NF-kappaB signaling | 156/7958 | 281/18723 | 6.66e-06 | 8.00e-05 | 156 |
GO:004312212 | Liver | HCC | regulation of I-kappaB kinase/NF-kappaB signaling | 138/7958 | 249/18723 | 2.47e-05 | 2.58e-04 | 138 |
GO:001095212 | Liver | HCC | positive regulation of peptidase activity | 110/7958 | 197/18723 | 1.04e-04 | 8.98e-04 | 110 |
GO:00467775 | Liver | HCC | protein autophosphorylation | 123/7958 | 227/18723 | 2.40e-04 | 1.80e-03 | 123 |
GO:00434097 | Liver | HCC | negative regulation of MAPK cascade | 98/7958 | 180/18723 | 7.88e-04 | 4.74e-03 | 98 |
GO:00510902 | Liver | HCC | regulation of DNA-binding transcription factor activity | 220/7958 | 440/18723 | 8.04e-04 | 4.82e-03 | 220 |
GO:001095012 | Liver | HCC | positive regulation of endopeptidase activity | 96/7958 | 179/18723 | 1.68e-03 | 8.79e-03 | 96 |
GO:19012242 | Liver | HCC | positive regulation of NIK/NF-kappaB signaling | 41/7958 | 69/18723 | 3.38e-03 | 1.54e-02 | 41 |
GO:00380611 | Liver | HCC | NIK/NF-kappaB signaling | 77/7958 | 143/18723 | 3.98e-03 | 1.76e-02 | 77 |
GO:004328012 | Liver | HCC | positive regulation of cysteine-type endopeptidase activity involved in apoptotic process | 70/7958 | 129/18723 | 4.58e-03 | 1.97e-02 | 70 |
GO:200105612 | Liver | HCC | positive regulation of cysteine-type endopeptidase activity | 79/7958 | 148/18723 | 4.82e-03 | 2.03e-02 | 79 |
Page: 1 2 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
NLRP12 | SNV | Missense_Mutation | novel | c.2759N>T | p.Arg920Leu | p.R920L | P59046 | protein_coding | tolerated(0.31) | probably_damaging(0.999) | TCGA-44-4112-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
NLRP12 | SNV | Missense_Mutation | c.2116C>G | p.Leu706Val | p.L706V | P59046 | protein_coding | deleterious(0) | benign(0.137) | TCGA-44-6774-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | alimta | SD | |
NLRP12 | SNV | Missense_Mutation | c.1394N>A | p.Ala465Glu | p.A465E | P59046 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-44-7672-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NLRP12 | SNV | Missense_Mutation | c.374N>G | p.Pro125Arg | p.P125R | P59046 | protein_coding | tolerated(0.55) | probably_damaging(0.94) | TCGA-50-5049-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
NLRP12 | SNV | Missense_Mutation | c.1453G>T | p.Gly485Cys | p.G485C | P59046 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-50-5930-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxotere | PD | |
NLRP12 | SNV | Missense_Mutation | c.1747G>T | p.Val583Phe | p.V583F | P59046 | protein_coding | deleterious(0.05) | possibly_damaging(0.572) | TCGA-50-5946-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | PD | |
NLRP12 | SNV | Missense_Mutation | c.1939C>A | p.His647Asn | p.H647N | P59046 | protein_coding | deleterious(0) | possibly_damaging(0.826) | TCGA-53-7624-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | PD | |
NLRP12 | SNV | Missense_Mutation | novel | c.1103N>A | p.Ala368Glu | p.A368E | P59046 | protein_coding | tolerated(0.2) | benign(0.315) | TCGA-55-6971-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
NLRP12 | SNV | Missense_Mutation | c.1710G>T | p.Glu570Asp | p.E570D | P59046 | protein_coding | tolerated(0.08) | benign(0.113) | TCGA-55-6985-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
NLRP12 | SNV | Missense_Mutation | novel | c.2176C>A | p.Leu726Met | p.L726M | P59046 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-55-6987-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |